用telitacicept,mycophenolate mofetil和葡萄糖皮质类药物的联合治疗免疫球蛋白A脏病:一个病例报告
Yan Shen1, Jin Yuan1, Shuang Chen1
1Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
World journal of clinical cases
|October 17, 2024
概括
泰利塔西通过抑制B细胞激活和减少免疫球蛋白A (IgA) 生产,有效地治疗IgA脏病. 这种新型疗法在IgA脏病患者中显示出对脏保护的前景.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫球蛋白A (IgA) 脏病的特征是IgA沉积在淋巴细胞中,导致炎症和脏损伤.
- 泰利塔西针对B淋巴细胞刺激剂 (BLyS) 和诱导增殖的配体 (APRIL),它们是B细胞激活和IgA生成的关键媒介.
- 这种机制表明Telitacicept在缓解IgA瘤病变进展方面的潜在治疗作用.
研究的目的:
- 评估Telitacicept作为IgA脏病的补充疗法的疗效和安全性.
- 评估Telitacicept对耐性IgA脏病患者功能和蛋白尿的影响.
主要方法:
- 一个24岁的女性被诊断出患有IgA脏病和焦点增殖性淋巴结膜炎的案例研究.
- 最初的治疗包括血管激素II受体阻断剂,激素和mycophenolate mofetil,但没有显著改善.
- 泰利塔西塞普被添加到治疗方案中,并对其对功能和蛋白尿的影响进行了监测.
主要成果:
- 添加Telitacicept导致功能恢复和蛋白尿的快速减少.
- 激素治疗成功地逐渐减少,并在Telitacicept的引入后停止.
- 在Telitacicept治疗期间没有观察到严重感染或相关并发症.
结论:
- 与激素和mycophenolate mofetil结合使用的telitacicept显示出作为IgA脏病的安全有效诱导疗法的潜力.
- 这种治疗方法可能为IgA脏病患者的管理提供了一种新策略,特别是那些对标准治疗反应不佳的患者.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:27Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
01:26Kidney Transplant II: Surgical Procedure
2
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
2
01:29Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126